Indian Stroke Association launches the Bangalore chapter of ‘Mission Brain Attack’
Strokes are affecting approximately 1.8 million people annually
Strokes are affecting approximately 1.8 million people annually
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
WHO estimates suggest that 150 million people worldwide are affected by Trachoma
We now rank 3rd in pharmaceutical production by volume and 14th by value
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
The acquisition will strengthen the overall company’s position as leading global CRO services partner
Subscribe To Our Newsletter & Stay Updated